Literature DB >> 22129258

The yin and yang of interleukin-2-mediated immunotherapy.

Jeffrey A Bluestone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22129258     DOI： 10.1056/NEJMe1110900

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  25 in total

Review 1.  The Role of Regulatory T Cells in Mesothelioma.

Authors:  Demelza J Ireland; Haydn T Kissick; Manfred W Beilharz
Journal:  Cancer Microenviron       Date:  2012-02-01

Review 2.  Regulatory T-cell therapy in transplantation: moving to the clinic.

Authors:  Qizhi Tang; Jeffrey A Bluestone
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

3.  IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells.

Authors:  Masayuki Mizui; Tomohiro Koga; Linda A Lieberman; Jessica Beltran; Nobuya Yoshida; Mark C Johnson; Roland Tisch; George C Tsokos
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

4.  Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity.

Authors:  Martin Vaeth; Carina A Bäuerlein; Tobias Pusch; Janina Findeis; Martin Chopra; Anja Mottok; Andreas Rosenwald; Andreas Beilhack; Friederike Berberich-Siebelt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-12       Impact factor: 11.205

Review 5.  Adoptive immunotherapy for cancer: harnessing the T cell response.

Authors:  Nicholas P Restifo; Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

Review 6.  Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.

Authors:  Denise Skrombolas; John G Frelinger
Journal:  Expert Rev Clin Immunol       Date:  2014-02       Impact factor: 4.473

7.  New perspectives of an old cytokine.

Authors:  Ali Raza; Mohamed T Shata
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

8.  CCR8+FOXp3+ Treg cells as master drivers of immune regulation.

Authors:  Yiftah Barsheshet; Gizi Wildbaum; Eran Levy; Alon Vitenshtein; Chika Akinseye; Jeremy Griggs; Sergio A Lira; Nathan Karin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-22       Impact factor: 11.205

9.  Amelioration of arthritis through mobilization of peptide-specific CD8+ regulatory T cells.

Authors:  Jianmei W Leavenworth; Xiaolei Tang; Hye-Jung Kim; Xiaoyang Wang; Harvey Cantor
Journal:  J Clin Invest       Date:  2013-02-08       Impact factor: 14.808

10.  The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus.

Authors:  Amit Golding; Sarfaraz Hasni; Gabor Illei; Ethan M Shevach
Journal:  Arthritis Rheum       Date:  2013-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.